Novo Nordisk board members step down after major shareholder dispute
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy…
Stock market today: Live updates
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., October…
Novo Nordisk and Omeros announce asset purchase and license
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease…
Novo Nordisk begins round of layoffs in United States: Reuters
A view shows a Novo Nordisk sign outside its office in Bagsvaerd, on the outskirts of Copenhagen, Denmark,…
What’s likely to move the market in the next trading session
Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…
Trump pharmaceutical tariff threat lessens after Pfizer deal
U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla (L) as he announces a deal with…
Eli Lilly plans $6.5 billion Texas manufacturing plant for obesity pill
A rendering of Eli Lilly’s manufacturing facility in Houston, Texas. Courtesy: Eli Lilly Eli Lilly on Tuesday said…
Eli Lilly obesity pill beats Novo Nordisk drug in diabetes trial
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March…
Eli Lilly to build $5 billion Virginia manufacturing facility
Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli…
CPI report health care inflation rises
Jose Luis Pelaez Inc | Digitalvision | Getty Images Health-care inflation is fueling higher coverage costs, setting the…
What’s likely to move the market in the next trading session
Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…
Novo Nordisk tells staff to return to office full-time
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy…